SARS-CoV-2 Vaccination Effectiveness in Rituximab-Treated Patients Affected by Pemphigus Vulgaris

J Invest Dermatol. 2023 Aug;143(8):1601-1604. doi: 10.1016/j.jid.2022.12.023. Epub 2023 Jan 28.
No abstract available

MeSH terms

  • COVID-19 Vaccines* / administration & dosage
  • COVID-19* / prevention & control
  • Humans
  • Immunologic Factors
  • Pemphigus* / drug therapy
  • Rituximab / adverse effects
  • SARS-CoV-2
  • Vaccination

Substances

  • COVID-19 Vaccines
  • Immunologic Factors
  • Rituximab